Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Moderna announced a $3 billion buyback program earlier in 2022 and then another $3 billion in August, which it's working on now. Combined, these represent roughly 10% of Moderna's entire market cap.
$MRNA is in a new major uptrend.
The reason for all this: Moderna is on the cusp of creating an infinite series of mRNA vaccines, to prevent HIV, various cancers, respiratory diseases, heart disease, any new Covid-19 variants, etc, etc, etc. All this, by using their patents that protect their quasi-robotic design and manufacturing method - yes, BionTech will lose in the courts, and will need to pay retroactive royalties to Moderna-
Moderna's appetite for antibody tech spurs $6M bet on Nona's heavy chain only platform
https://www.fiercebiotech.com/biotech/modernas-appetite-antibody-tech-spurs-6m-bet-nonas-heavy-chain-only-platform
Celebrating the 10th Anniversary of the International mRNA Health Conference
https://www.modernatx.com/media-center/all-media/blogs/mRNA-health-conference?tc=soc_fbe607&cc=1009
The fact the Merck invested and basically validated what they saw at moderna's labs, says it all. The cancer trials will yield positive results as will the stick price. moderna will have a different story then.
https://www.merck.com/news/merck-and-moderna-announce-exercise-of-option-by-merck-for-joint-development-and-commercialization-of-investigational-personalized-cancer-vaccine/
How mRNA vaccines could fight Ebola
https://www.nature.com/articles/d41586-022-03661-0
Quebec :
It was a wonderful day in la Belle Province of #Quebec as we celebrated the groundbreaking of our #mRNA #vaccine manufacturing facility in Laval with @JustinTrudeau @FP_Champagne @Cskeete @StphanBoyer and our distinguished guests. pic.twitter.com/TmuqUbm6mW
— Moderna (@moderna_tx) November 10, 2022
Nearly 2% of healthy infants hospitalized with RSV before first birthday, study finds
https://www.cnbc.com/2022/11/10/healthy-infants-face-significant-risk-of-rsv-hospitalization-study.html
$MRNA
Harbour BioMed Enters into a License and Collaboration Agreement with Moderna
he strategic collaboration will focus on discovering and developing nucleic acid-based immunotherapies for select oncology targets using the Company's proprietary heavy chain only antibody discovery platform (HCAb).
https://www.prnewswire.com/news-releases/harbour-biomed-enters-into-a-license-and-collaboration-agreement-with-moderna-301675149.html
Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
Nov 10, 2022
https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-third-quarter-2022-financial-results
On December 6, the Company will hold its virtual R&D Day with leadership and renowned oncology experts to present an in-depth overview of the Company’s viral immunotherapy platforms and clinical pipeline including additional data from its phase 2 clinical trial of CAN-2409 in combination with anti-PD-1 or PD-L1 agents in patients with stage III/IV non-small cell lung cancer.
Moderna, new headquarters in Italy at the beginning of 2023 (and starting with 20 hires)
https://news.italy24.press/local/amp/179844
President Joe Biden and Democrats will no longer have full control of the White House and Congres,,,,,,,
So a split Congress could be a positive for Wall Street, and could be good news for defense firms, private prisons and drugmakers. Then again, markets may have already priced some that in.
Feds hold groundbreaking ceremony for Moderna's mRNA vaccine factory in Montreal area
https://montreal.ctvnews.ca/feds-hold-groundbreaking-ceremony-for-moderna-s-mrna-vaccine-factory-in-montreal-area-1.6142301
I want to see who the winner is ;> Patent wars: Moderna’s battle for the spoils of Covid vaccines
Ending of pharma group’s IP truce spells fight for future of mRNA technology
https://www.ft.com/content/5769f077-641e-4d37-adc6-7634c59b6d5d?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev
A combination vaccine for flu and COVID-19 is in the works. Here's what to know.
huge news: Human trials are underway to assess the safety and efficacy of a flu-COVID combination vaccine.
Moderna has finished enrolling trial participants while Pfizer-BioNTech isn't too far behind.
Health experts say these combination vaccines could be available as early as next flu season.
https://eu.usatoday.com/story/news/health/2022/11/07/flu-covid-vaccine-pfizer-moderna/8257444001/
REV 3.4B, EPS 2.53
-2022 est 18 - 19B$
-Pipeline 48 programs, 45 categories, 35 are in clinical trials
-PVC PII data expected 4Q22
-RSV PIII data expected this winter
-FLU PIII data 1Q23
Cash/cash equivalent at end of 3Q, 17B$
How money was spent
-Repurchase 24M share for 2.9B$ (complete) reduces outstanding shares (405M to 387M)
-Started a 2d buyback plan (3B$) as announced in AUG22
-Reinvested 820M$ in R&D (pipeline)
-Losses, 333M$ write off on CV19 product, and 102M$ from canceled purchase agreements
$MRNA multibaggers
Tecovirimat is effective against human monkeypox virus in vitro at nanomolar concentrations
https://www.nature.com/articles/s41564-022-01269-8
November and December news in release!!!! Oral Presentation Title: First efficacy and multi-omic analysis data from phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma
CAN-2409 is also being evaluated in multiple phase 2 and phase 3 clinical trials for lung, brain, pancreatic, and prostate cancers.
but we will have more new data and a new cohort of 11 patients in December this year."
https://www.healthleadersmedia.com/pharma/just-two-years-helm-ceo-paul-peter-tak-transforms-candel-and-cancer-treatment
The U.S. is officially in a flu epidemic, federal health officials say. They’re preparing to deploy troops and ventilators if necessary
https://fortune.com/well/2022/11/04/us-united-states-in-flu-epidemic-federal-health-officials-say-cdc-hhs-rsv-covid-omicron-2022/
2023 Advanced Purchase Agreements
BIG COMPANY,,,,,,,,,
Confirmed APAs, as well as previously deferred product sales, currently represent $4.5-$5.5 billion in anticipated product sales in 2023. The Company expects additional sales in key markets, including the U.S., E.U., Japan, Middle East, Latin America and Asia Pacific in 2023.
From the end of the third quarter of 2021 to the end of the third quarter of 2022, the Company repurchased 24 million shares, reducing the number of common shares outstanding from 405 million to 387 million, more than offsetting 5 million shares of common stock issued in connection with equity compensation over this period.
CMV vaccine (mRNA-1647) pivotal Phase 3 study, known as CMVictory, is ongoing.
$MRNA
The good news is that RSV vaccines are on the way:
Moderna Inc. says its vaccine for respiratory syncytial virus, better known as RSV, could be ready for commercialization as soon as next year.
The Cambridge drugmaker is currently running a Phase 3 trial of its mRNA-based RSV vaccine. Data is expected sometime this winter; if it meets expectations, then Moderna could launch it before the fall 2023 sick season, executives said on the company's third-quarter earnings call Thursday morning.
$MRNA
U.S. faces highest flu hospitalization rate in a decade with young kids and seniors most at risk
Cases of respiratory syncytial virus, or RSV, is also increasing in almost every region of the U.S.
$MRNA Phase 3 RSV vaccine efficacy data could read out this winter
Phase 3 flu vaccine immunogenicity data expected in 1Q23
https://www.cnbc.com/2022/11/04/us-faces-highest-flu-hospitalization-rate-in-a-decade.html
Beth, I'm not reporting on this any more. Should I be worried about this? $MRNA
GREEN DAY LOL...... MRNA WINNER$$$$$$$$
Reflecting on More Than a Decade of Progress on mRNA Science:
read about the development of our mRNA platform and pipeline which includes 47 programs in development, including 31 in clinical studies.
https://endpts.com/sp/reflecting-on-more-than-a-decade-of-progress-on-mrna-science/
ER is good: Approximately $61 Million of International Sales in the Third Quarter –
As of September 30, 2022, we had $109.7 million in cash and cash equivalents compared with $103.1 million at December 31, 2021.
As of September 30, 2022, we had outstanding purchase orders associated with manufacturing obligations in the aggregate amount of approximately $21.8 million.
https://investor.siga.com/news-releases/news-release-details/siga-reports-financial-results-three-and-nine-months-ended-0
Biden Admin Renews Public Health Emergency Over Monkeypox
https://www.zerohedge.com/medical/biden-admin-renews-public-health-emergency-over-monkeypox
impatient mannequins$$$$$$$$
money machine moderna!!!! green
Primary efficacy analysis from Phase 2 study for personalized cancer vaccine program (mRNA-4157/V940) expected in 4Q22
Phase 3 RSV vaccine efficacy data could read out this winter
Phase 3 flu vaccine immunogenicity data expected in 1Q23
BIG NEWS IMMINENT$$$$$$$$$$
Cash Position: Cash, cash equivalents and investments as of September 30, 2022 and December 31, 2021 were $17.0 billion and $17.6 billion, respectively.
2023 Advanced Purchase Agreements
Confirmed APAs, as well as previously deferred product sales, currently represent $4.5-$5.5 billion in anticipated product sales in 2023. The Company expects additional sales in key markets, including the U.S., E.U., Japan, Middle East, Latin America and Asia Pacific in 2023.
Share Repurchase Program
The $3 billion share repurchase program announced in February 2022 was completed early in the fourth quarter 2022. The Company has commenced repurchases from the additional $3 billion program announced in August 2022.
Moderna now has 48 programs in development across 45 development candidates[1], of which 35 are currently in active clinical trials. The Company's updated pipeline can be found at www.modernatx.com/pipeline. Moderna and collaborators have published more than 130 peer reviewed manuscripts.
Cash Used for Repurchases of Common Stock: Cash used for repurchases of common stock was $2.9 billion for the nine months ended September 30, 2022. Moderna did not conduct share repurchases prior to the fourth quarter of 2021. From the end of the third quarter of 2021 to the end of the third quarter of 2022, the Company repurchased 24 million shares, reducing the number of common shares outstanding from 405 million to 387 million, more than offsetting 5 million shares of common stock issued in connection with equity compensation over this period.
now or never$$$$$$$$
Third quarter 2022 revenues of $3.4 billion; GAAP net income of $1.0 billion and GAAP diluted EPS of $2.53
https://investors.modernatx.com/news/news-details/2022/Moderna-Reports-Third-Quarter-2022-Financial-Results-and-Provides-Business-Updates/default.aspx
There is a new video just out today on youtube featuring Bob Langer expressing his hopes and perspective on Moderna's personal cancer vaccine. The video: "Breaking down biotech innovation with Dr. Bob Langer."
WHO declares monkeypox still a global health emergency
WHO kept monkeypox on its highest alert level
https://www.foxnews.com/health/who-declares-monkeypox-still-global-health-emergency
Ministry of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.222
Moderna, Inc.
Tue, November 1, 2022 at 6:30 AM
all over the world pay for the war!
This is the evil of the economy
when it ends,Things will change soon....
In the span of just seven trading sessions, there will be four major events that could shape the market’s outlook for the rest of the year -- and potentially prompt a rapid about-face by confounding expectations.
On Nov. 2, the Federal Reserve will announce its latest interest-rate decision and give hints about its path forward, possibly signaling plans to ease back from the aggressive pace of hikes that’s threatening to drive the economy into a recession.
Two days later, the October jobs report will provide an important look at how much hiring is slowing. Then on Nov. 8, the mid-term elections may usher in a change in which party controls Congress. And finally, on Nov. 10 there’s the consumer price index, a report that’s played a key role in shaping expectations for the Fed’s path since inflation roared back to a four-decade high.
let's see what will happen........
On Tuesday, Morgan Stanley analyst Matthew Harrison provided an encouraging view of Moderna's upcoming analysis of a phase 2 study for its personalized cancer vaccine as an adjuvant treatment for patients with high-risk melanoma. Harrison believes Merck's recent decision to exercise its option to jointly develop and commercialize the drug suggests the results will be positive.
RELAX$$$$$$$
Moderna will join Pfizer an announce $100+ shot after government buy ends. They don't need to see 300million any more just 50 million will generate 5 Billion a year!!!!!!!!!
Plus next year they roll out the flu shot for an even bigger market.
RELAX!!!!!!